Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Federal Trade Commission
Express Scripts
Fish and Richardson
McKesson
Cerilliant
Citi
Teva
Deloitte
Boehringer Ingelheim

Generated: February 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,994,220

« Back to Dashboard

Which drugs does patent 7,994,220 protect, and when does it expire?

Patent 7,994,220 protects SAVELLA and is included in one NDA.

This patent has thirty-one patent family members in twenty-two countries.
Summary for Patent: 7,994,220
Title:Milnacipran for the long-term treatment of fibromyalgia syndrome
Abstract: The present invention is directed to methods for providing long-term treatment of fibromyalgia syndrome (FMS) by administering a dual re-uptake inhibitor to a patient with FMS. More particularly, the present invention is directed to the long-term treatment of FMS by administering a norepinephrine-serotonin reuptake inhibitor (NSRI) to a patient with FMS.
Inventor(s): Rao; Srinivas G. (Encinitas, CA), Gendreau; Michael (Poway, CA), Kranzler; Jay D. (La Jolla, CA)
Assignee: Cypress Bioscience, Inc. (San Diego, CA)
Application Number:11/535,237
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 7,994,220

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan Sales Llc SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-001 Jan 14, 2009 AB RX Yes No ➤ Sign Up ➤ Sign Up MANAGEMENT OF FIBROMYALGIA ➤ Sign Up
Allergan Sales Llc SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-002 Jan 14, 2009 AB RX Yes No ➤ Sign Up ➤ Sign Up MANAGEMENT OF FIBROMYALGIA ➤ Sign Up
Allergan Sales Llc SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-003 Jan 14, 2009 AB RX Yes Yes ➤ Sign Up ➤ Sign Up MANAGEMENT OF FIBROMYALGIA ➤ Sign Up
Allergan Sales Llc SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-004 Jan 14, 2009 AB RX Yes No ➤ Sign Up ➤ Sign Up MANAGEMENT OF FIBROMYALGIA ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,994,220

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation 2008112192 ➤ Sign Up
New Zealand 593199 ➤ Sign Up
New Zealand 567271 ➤ Sign Up
Norway 20081951 ➤ Sign Up
Malaysia 145340 ➤ Sign Up
Morocco 31720 ➤ Sign Up
South Korea 20080055967 ➤ Sign Up
Japan 2009510080 ➤ Sign Up
Japan 6014702 ➤ Sign Up
Japan 2015134811 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Teva
Cipla
Harvard Business School
Medtronic
Farmers Insurance
Deloitte
Moodys
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot